Company Profile

Industry Sector: Pharmaceuticals

Company Overview: Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately owned oral drug delivery specialty firm focused on R&D efforts to enhance the oral absorption of investigational and marketed compounds currently not suitable for this most convenient route of drug administration. We have developed a variety of patented technologies for improving oral absorption of drug candidates, including prodrug and carrier technologies as well as time and rate controlled delivery systems. Through customized problem-solving strategies and tailored delivery solutions, TSRL is able to provide patentable oral drug delivery technologies for drug candidates.

Target Market(s): Oral drug delivery of antiviral and anticancer therapeutics.

Management

Leadership:
Gordon Amidon, President and CSO
John Hilfinger, Executive Vice President
Elke Lipka, Vice President Business Development

Scientific Advisory Board:
John Drach, Professor of Virology, University of Michigan
Steven Goldstein, Professor of Orthopaedic Surgery and Bioengineering, University of Michigan
Charles McKenna, Professor of Chemistry at the University of Southern California
Blake Roessler, Associate Professor of Internal Medicine, University of Michigan
Clifford Rosen, Director, Maine Center for Osteoporosis Research

Key Value Drivers

Technology: TSRL has developed oral prodrug and carrier technologies that address poor intestinal permeability of drugs by enabling the utilization of intestinal transporter "shuttles" to increase absorption. Preclinical studies have demonstrated increases in absorption of low permeability compounds up to 20-fold.

Competitive Advantage: We have applied our proprietary technologies to a number of antiviral compounds to develop oral therapies for diseases for which no current treatment option exists, such smallpox and influenza. There is huge medical need for treatment options for such infections from bioterrorism and pandemic perspective, as well as for treating complications arising from vaccinations. Our technology solutions result in patentable new chemical entities, which ensure full product exclusivity with shorter development timelines and faster ROIs.

Plan & Strategy: Seeking a strategic partner.

*Technology funded by the NIAID and being commercialized under the NIH-CAP.

Product Pipeline

<table>
<thead>
<tr>
<th>Stage</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td>Cidofovir-Prodrug</td>
</tr>
<tr>
<td>Lead</td>
<td>Vidarabine-Prodrug</td>
</tr>
<tr>
<td>Lead</td>
<td>Anticancer-Prodrug</td>
</tr>
<tr>
<td>IND</td>
<td>BAC-Zanamivir</td>
</tr>
<tr>
<td>IND</td>
<td>BAC-Alendronate</td>
</tr>
</tbody>
</table>

Legend:
- Ongoing
- Completed